Publications Non-Small Cell Lung Cancer

  • « overview publications


  • The Journal of Clinical Oncology has recently published an article on "Clinical Cancer Advances 2009: Marjor Research Advances in Cancer Treatment, Prevention and Screening - A Report from the American Society of Clinical Oncology" (N. Petrelli et al., Epub ahead of print, November 6, 2009).

    CECOG is proud that the JMEN trial - which was cosponsored by CECOG - is mentioned in this publication as having changed the standard of care in patients with non small cell lung cancer.

    This study was published recently in The Lancet (T. Ciuleanu, T. Brodowicz, C. Zielinski, et al.: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374:1432-40).

  • Significant Prolongation of Overall Survival in Non Small Cell Lung Cancer by Maintenance Therapy with Pemetrexed: Participation of the Central European Cooperative Oncology Group (CECOG) in the Formulation of a New Treatment Concept.

    continue »

  • Signifikante Verlängerung der Überlebensdauer bei Lungenkarzinom durch neue Therapiestrategie: Beteiligung der Central European Cooperative Oncology Group (CECOG) an der Erarbeitung eines neuen Behandlungskonzepts.

    weiter »

  • Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study.

    T. Ciuleanu, T. Brodowicz, CP. Belani, JH Kim. M. Krzakowski, E. Laack, YL. Wu, P. Peterson, S. Adachi, C. Zielinski

    J. Clin. Oncol (supplement to 26) 2008: # 8011

  • Tolerability of pemetrexed versus placebo as a maintenance therapy in Advanced non-Small Cell Lung Cancer: Evidence from a large randomized study.

    C. Zielinski, S. Yang, A. Santoro, R. Ramlau, A. Liepa, P. Peterson, T. Brodowicz, J. Madhavan, F. Franke, B. Cucevic.

    J. Clin. ONcol (Supplement to 26) 2008: # 8060

  • The manuscript "Cisplatin and Gemcitabine First-Line Cheomtherapy Followed by Maintenance Gemcitabine or Best Supportive Care in Advanced Non-Small Cell Lung Cancer: A Phase III Trial" has been published in Lung Cancer (2006) vol. 52; p155 - 163).

    Certificate

    Download: article (pdf - 257kb)

  • Gemcitabine and Cisplatin (GC) +/- Subsequent Maintenance Therapy with Single-Agent Gemcitabine in Advanced Non-small Cell Lung Cancer (NSCLC): Preliminary Results of a Randomized Trial of the Central European Cooperative Oncology Group (CECOG).

    M. Krzakowski, M. Wenczl, T. Brodowicz, V. Tzekova, R. Ramlau, N. Ghilezan, B. Cucevic, K. Gyurkovits, E. Ulsperger, C. Zielinski, M. Zwitter.

    World Conference on Lung Cancer, 2003

  • Gemcitabine and Cisplatin (GC) +/- Subsequent Maintenance Therapy with Single-Agent Gemcitabine in Advanced Non-small Cell Lung Cancer (NSCLC): Preliminary Results of a Randomized Trial of the Central European Cooperative Oncology Group (CECOG).

    M. Krzakowski, M. Wenczl, T. Brodowicz, V. Tzekova, R. Ramlau, N. Ghilezan, B. Cucevic, E. Ulsperger, C. Zielinski, M. Zwitter.

    Proc. Am. Soc. Clin. Oncol. 2004


  • Delay in time to worsening of symptoms of advanced non-small cell lung cancer patients using gemcitabine maintenance therapy.

    P. Peterson, M. Zwitter, M. Krzakowski, M. Wenczl, V. Tzekova, R. Ramlau, T. Ciuleanu, A. Liepa, C. Zielinski, T. Brodowicz

    Supplement to Journal of Clin. Oncol. 2006, 24, 399s, abstract 7140



For publications of the results of the Consensus Conferenences
see Consensus Statements